Privately-held Italian drugmaker Menarini and its oncology-focused subsidiary Stemline Therapeutics have entered into a ...

Several of the USA’s biggest pharmacy benefit managers (PBMs) have generated billions of dollars in revenue by charging ...

Shares of US biotech Regenxbio surged 18.4% in pre-open trading Tuesday after announced a strategic partnership with Japan’s ...

Japanese drugmaker Daiichi Sankyo announced that it will pay Glycotope GmbH $132.5 million to acquire intellectual property ...

Verastem Oncology licenses VS-7375 rights from GenFleet Therapeutics, aiming to target KRAS-driven cancers. Early Phase I ...

Mabwell Bioscience plans a secondary listing in Hong Kong to bolster development and global expansion. The move targets Hong ...

Seattle, USA- based clinical-stage CART-T therapies developer Umoja Biopharma, today announced the closing of a $100 million ...

Turkish drugmaker Er-Kim has signed a distribution agreement with Germany’s MEDICE Health Family to commercialize Vafseo ...

US late-stage biopharma firm Sling Therapeutics today announced top-line efficacy and safety data from the Phase IIb/III LIDS ...

Japanese drugmaker Eisai and US partner Biogen announced today that the US Food and Drug Administration (FDA) has accepted Eisai’s Biologics License Application (BLA) for lecanemab-irmb (US brand name ...

German independent biomedical research institute BioMed X has launched a new collaboration with Japanese drugmaker Daiichi ...

Swiss pharma giant Novartis has expressed its satisfaction at a decision by the US Court of Appeals for the Federal Circuit ...